The Long Road to A Breast Cancer Vaccine

Pink Vaccine Transparent.png

For those of you who are new to my story, I was diagnosed with bi-lateral breast cancer in December of 2009. To borrow the words from Queen Elizabeth II, 2010 was my “Annus Horribilis”.

The year included a double mastectomy with expanders, hysterectomy and implant exchange surgery.  Not to mention numerous diagnostic tests and procedures.  I was however, more fortunate than many of my breast cancer sisters as the Oncotype DX had been recently approved and my results and no lymph node involvement would spare me from chemotherapy.

A bright light is a very dark tunnel was when I happened upon a video of a research doctor at the Cleveland Clinic’s Learner Research Institute presenting his research findings before Congress of the discovery of a preventive breast cancer vaccine. That Doctor is Dr. Vincent Tuohy who had recently proven his theory by using a mouse model.  Those same mice that were used by all researchers to study breast cancer. What!!!! I said….first in disbelief and then in anger after I spoke with Dr. Tuohy and learned that the only thing preventing his discovery from going from bench to bedside and testing in humans was money for the clinical trials.

Over the next ten years, I would coordinate with four other women who supported the vaccine and worked tirelessly to raise awareness in hope of obtaining funding.  Sadly, one passed away from her disease early on (inflammatory breast cancer).  Some in the group would move on but my dear friend Toni Turchi and myself would continue fundraising along with Marjorie Moyer and the wonderful women at Brakes for Breasts.  Toni and I would attend conferences including the San Antonio Breast Cancer Convention, the largest in the world, and support Dr. Tuohy.  Possibly the most dramatic of our efforts was along with Marjorie we actually lobbied Congress and gained support from Congresswoman Debbie Wasserman Shultz, herself a breast cancer survivor.

The breakthrough came in 2017 when he was awarded a grant from the Department of Defense to proceed with the phase I clinical trials.  I am honored to serve as an advocate on the vaccine trial team which meets weekly and we will finally see this vaccine tested in human trials this Summer.

I will now share Dr. Tuohy’s story with you in his own words.  This information is also on the Brakes for Breasts Website. I pray that when we finally test this vaccine, 2021 will be the year we celebrate a cure for breast cancer,  or as Dr. Tuohy says, “Prevention is the Cure.”

CURRENT STATUS OF THE VACCINE....A Word from Dr. Tuohy

There are two major components of the TNBC vaccine: 1) the target protein, namely, human α-lactalbumin. This is the specific protein against which we plan to induce a well-defined immune response associated with inhibition and prevention of breast cancer growth; and 2) the “adjuvant”, an inflammatory substance that non-specifically irritates and activates what is called the innate immune system that orchestrates the defined specific response to the α-lactalbumin target protein. Both of these components must be made under very detailed and controlled conditions and must meet the very complex analytic requirements of the US Food and Drug Administration (FDA). This analytic process is called Good Manufacturing Practice (GMP). It may sound like a benign name for a manufacturing process, but it is well-known to represent an extremely complicated process that requires a fastidious attention to details that will convince the FDA that our reagents can be produced in a repeatable manner with no chance of containing contaminants that may harm humans injected with the substance.

This GMP manufacturing process is extremely expensive and requires specialized facilities specifically dedicated to this effort. Our human α-lactalbumin was made under GMP conditions by a company in California at a cost of approximately $850k. The adjuvant is being manufactured in a GMP facility in Switzerland at a cost of approximately $750k. However, after GMP manufacturing of our adjuvant, we will have additional expenses for performing sterility studies as well as fill and finish studies in vials for use in clinical trials. I anticipate that these costs will exceed $300k. There are several other additional costs related to preclinical toxicology studies and prolonged stability studies that will easily consume the remainder of the $2.2 million allocated from our Department of Defense grant for preparing the vaccine for our clinical trials.

A few months ago, I was hoping that these GMP products would be ready in time for us to apply to the FDA for permission to start recruiting for our phase Ia clinical trial by the fall of 2020. However, the human race has since been stalked by the SARS-COV-2 virus that has caused the current COVID-19 pandemic. This pandemic has caused unanticipated issues that will likely delay recruitment of test subjects until the first quarter of 2021. While we are waiting for completion of all regulatory requirements, we are currently assembling our application to the FDA to obtain permission to use our Investigational New Drug (IND) in clinical trials.

I have provided only the core basic things that must be done to get permission from the FDA to test our vaccine in human subjects. I simply want to give you an idea how complicated this process is and why it takes so long and costs so much. Meanwhile, when travel becomes acceptable again, I am hoping to attend appropriate meetings to inform the medical research community about what we are doing. In addition, we have submitted several grants for supporting our lab work and have submitted several patent applications to obtain sufficient intellectual property (IP) protection to attract commercial licensing partners from the pharmaceutical/biotech industry.

 

 The latter is necessary to provide a licensing partner with a monopoly to develop and test our vaccines in very expensive advanced phase II/III clinical trials to determine whether our vaccine is effective in inhibiting the growth and emergence of breast tumors and whether it has potential for commercialization. Without the expensive IP in the form of several patents that cover all industrialized countries, our vaccines would be in the public domain without any possibility of receiving interest from the pharmaceutical/biotech industry. Basically, it would be dead and finished. Thus, strong IP is an essential but costly part of our overall effort to provide the general public with our vaccine. The expenses for patent protection have been absorbed by the Cleveland Clinic. Our strong IP has worked since we formed a strategic alliance and licensing arrangement with Anixa Biosciences, Inc. (ANIX) on July 17, 2019. This arrangement will provide us with access to investor money needed to finance our very expensive phase II/III clinical trials. I must emphasize that this licensing agreement provided absolutely no money or other assets to me or to my research program.

In addition to all of the ongoing efforts to move our TNBC vaccine through the FDA regulatory process, we are finishing the preclinical testing of our preventive ovarian cancer vaccine. This vaccine, like the TNBC vaccine, can also be used effectively to treat established growing ovarian tumors and will have to go through two phase I trials similar to the clinical plan we have for our TNBC vaccine. Currently, I have no funding for these clinical trials and am actively seeking such funding. Finally, I would like to inform you that I must rely on philanthropy for paying the modest salaries of the laboratory and regulatory personnel involved in getting our vaccine ready for clinical trials. These salaries were not included in the DoD grant because of the limits the DoD provided for funding this project. I would greatly appreciate continued support from Brakes for Breasts to cover all of the unfunded expenses involved in our very expensive clinical trials designed ultimately to prevent TNBC and ovarian cancer and thereby profoundly alter the natural history of these lethal diseases.